Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 1.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) delivered earnings and revenue surprises of 8.47% and 0.91%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Atlassian's (TEAM) Q3 results are likely to reflect the benefits of increased demand for its solutions amid accelerated digital transformations and cloud adoptions.
DraftKings' (DKNG) first-quarter 2023 performance is likely to have benefited from the robust demand for mobile sports betting and expansion efforts in new states.
Certara, Inc. (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shake Shack, Wingstop, AssetMark Financial, Primerica and Certara are included in this Analyst Blog.
We have narrowed our search to five stocks that are set to report first-quarter 2023 earnings results. These are: SHAK, WING, AMK, PRI and CERT.
Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.
Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success.